Harbour Antibodies BV Sustainability Profile
Harbour Antibodies BV, a leading player in the biotechnology sector, is headquartered in the Netherlands and operates extensively across Europe and North America. Founded in 2011, the company has established itself as a pioneer in the development of innovative antibody-based solutions for research and therapeutic applications. Specialising in custom monoclonal antibodies, Harbour Antibodies offers unique services that include the generation of high-affinity antibodies tailored to specific targets. Their proprietary technologies and commitment to quality have positioned them as a trusted partner in the life sciences industry. With a strong focus on advancing antibody engineering, Harbour Antibodies BV has achieved significant milestones, including collaborations with prominent research institutions and biopharmaceutical companies, solidifying its reputation as a key contributor to the field of immunology.
DitchCarbon Score
How does Harbour Antibodies BV's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Harbour Antibodies BV's score of 3 is lower than 99% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Harbour Antibodies BV's reported carbon emissions
Harbour Antibodies BV, headquartered in the Netherlands (NL), currently does not report any specific carbon emissions data, as indicated by the absence of emissions figures in kg CO2e. Furthermore, there are no documented reduction targets or climate pledges associated with the company. As a current subsidiary, Harbour Antibodies BV's climate commitments and emissions data may be influenced by its corporate family relationships; however, no specific initiatives or targets have been cascaded from a parent organization. In the context of the biotechnology industry, companies are increasingly expected to adopt robust climate strategies and transparency in emissions reporting. While Harbour Antibodies BV has not yet established measurable targets or disclosed emissions data, the industry trend suggests a growing emphasis on sustainability and carbon footprint reduction.
How Carbon Intensive is Harbour Antibodies BV's Industry?
How Carbon Intensive is Harbour Antibodies BV's Location?
Harbour Antibodies BV's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Harbour Antibodies BV has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
